Genentech reports detailed OS data for Tecentriq combo in first-line non-squamous NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported additional survival data from the Phase III IMpower150 trial evaluating Tecentriq atezolizumab in 1,202 chemotherapy-naïve patients with advanced stage IV non-squamous non-small cell lung cancer (NSCLC). First-line treatment with Tecentriq plus Avastin bevacizumab, paclitaxel

Read the full 438 word article

How to gain access

Continue reading with a
two-week free trial.